LDL-lowering therapy and the risk of prostate cancer: A meta-analysis of 6 randomized controlled trials and 36 observational studies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Tan, Ping ^a   Wei, Shiyou ^a   Tang, Zhuang ^a   Gao, Liang ^a   Zhang, Chen ^a   Nie, Pan ^a   Yang, Lu ^a   Wei, Qiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT;

BIOSTATISTICS; HUMAN; MALE; META ANALYSIS; OBSERVATIONAL STUDY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; BIOSTATISTICS; HUMANS; MALE; OBSERVATIONAL STUDIES AS TOPIC; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84963788176     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24521     Document Type: Article

References (57)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics. CA-Cancer J. Clin. 64, 9-29 (2014).
2. Carlberg, M. et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J. Biol. Chem. 271, 17453-17462 (1996).
3. Wong, W. W., Dimitroulakos, J., Minden, M. D. & Penn, L. Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508-519, doi: 10.1038/sj.leu.2402476 (2002).
4. Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug. Discov. 4, 977-987 (2005).
5. Dulak, J. & Jozkowicz, A. Anti-Angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Tar. 5, 579-594 (2005).
6. Bonovas, S., Filioussi, K. & Sitaras, N. M. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer 123, 899-904, doi: 10.1002/ijc.23550 (2008).
7. Bansal, D., Undela, K., D'Cruz, S. & Schifano, F. Statin use and risk of prostate cancer: a meta-Analysis of observational studies. PLoS One 7, e46691, doi: 10.1371/journal.pone.0046691 (2012).
8. Spruance, S. L., Reid, J. E., Grace, M. & Samore, M. Hazard ratio in clinical trials. Antimicrob. Agents Ch. 48, 2787-2792, doi: 10.1128/aac.48.8.2787-2792.2004 (2004).
9. de Lemos, M. L. How to survive the survival plots. Lancet. 360, 954, doi: 10.1016/s0140-6736(02)11063-4 (2002).
10. Zhang, J. & Yu, K. F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 280, 1690-1691 (1998).
11. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch. Intern. Med. 153, 1079-1087 (1993).
12. Friis, S. et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114, 643-647, doi: 10.1002/ijc.20758 (2005).
13. Platz, E. A. et al. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 98, 1819-1825, doi: 10.1093/jnci/djj499 (2006).
14. Flick, E. D. et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidem. Biomar. 16, 2218-2225, doi: 10.1158/1055-9965.epi-07-0197 (2007).
15. Boudreau, D. M., Yu, O., Buist, D. S. & Miglioretti, D. L. Statin use and prostate cancer risk in a large population-based setting. Cancer Cause. Control. 19, 767-774, doi: 10.1007/s10552-008-9139-4 (2008).
16. Friedman, G. D. et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidem. Dr. S. 17, 27-36, doi: 10.1002/pds.1507 (2008).
17. Smeeth, L., Douglas, I., Hall, A. J., Hubbard, R. & Evans, S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br. J. Clin. Pharmaco. 67, 99-109, doi: 10.1111/j.1365-2125.2008.03308.x (2009).
18. Breau, R. H. et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J. Urol. 184, 494-499, doi: 10.1016/j.juro.2010.03.149 (2010).
19. Haukka, J. et al. Incidence of cancer and statin usage-record linkage study. Int. J. Cancer 126, 279-284, doi: 10.1002/ijc.24536 (2010).
20. Hippisley-Cox, J. & Coupland, C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 340, c2197, doi: 10.1136/bmj.c2197 (2010).
21. Murtola, T. J. et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int. J. Cancer 127, 1650-1659, doi: 10.1002/ijc.25165 (2010).
22. Farwell, W. R., D'Avolio, L. W., Scranton, R. E., Lawler, E. V. & Gaziano, J. M. Statins and prostate cancer diagnosis and grade in a veterans population. J. Natl. Cancer Inst. 103, 885-892, doi: 10.1093/jnci/djr108 (2011).
23. Fowke, J. H. et al. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Cause. Control. 22, 417-426, doi: 10.1007/s10552-010-9713-4 (2011).
24. Jacobs, E. J., Newton, C. C., Thun, M. J. & Gapstur, S. M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71, 1763-1771, doi: 10.1158/0008-5472.can-10-2953 (2011).
25. Tan, N., Klein, E. A., Li, J., Moussa, A. S. & Jones, J. S. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J. Urol. 186, 86-90, doi: 10.1016/j.juro.2011.03.004 (2011).
26. Chan, J. M. et al. Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidem. Biomar. 21, 1886-1888, doi: 10.1158/1055-9965.epi-12-0816 (2012).
27. Lehman, D. M., Lorenzo, C., Hernandez, J. & Wang, C. P. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes. Care. 35, 1002-1007, doi: 10.2337/dc11-1829 (2012).
28. Freedland, S. J. et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer P. D. 16, 254-259, doi: 10.1038/pcan.2013.10 (2013).
29. Lustman, A., Nakar, S., Cohen, A. D. & Vinker, S. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer P. D. 17, 6-9, doi: 10.1038/pcan.2013.34 (2013).
30. Chen-Pin, W. et al. Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes. Ann. Transl. Med. Epidemiol. 1 (2014).
31. Morote, J. et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int. J. Mol. Sci. 15, 13615-13623, doi: 10.3390/ijms150813615 (2014).
32. Platz, E. A. et al. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J. Urol. 192, 379-384, doi: 10.1016/j.juro.2014.01.095 (2014).
33. Nordstrom, T., Clements, M., Karlsson, R., Adolfsson, J. & Gronberg, H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur. J. Cancer 51, 725-733, doi: 10.1016/j.ejca.2015.02.003 (2015).
34. Blais, L., Desgagne, A. & LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med. 160, 2363-2368 (2000).
35. Graaf, M. R., Beiderbeck, A. B., Egberts, A. C., Richel, D. J. & Guchelaar, H. J. The risk of cancer in users of statins. J. Clin. Oncol. 22, 2388-2394, doi: 10.1200/jco.2004.02.027 (2004).
36. Kaye, J. A. & Jick, H. Statin use and cancer risk in the General Practice Research Database. Brit. J. Cancer 90, 635-637, doi: 10.1038/sj.bjc.6601566 (2004).
37. Shannon, J. et al. Statins and prostate cancer risk: a case-control study. Am J. Epidemiol. 162, 318-325, doi: 10.1093/aje/kwi203 (2005).
38. Singal, R., Khurana, V., Caldito, G. & Fort, C. Statins and prostate cancer risk: a large case-control study in veterans. J. Clin. Oncol. 23, 1004 (2005).
39. Murtola, T. J., Tammela, T. L., Lahtela, J. & Auvinen, A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidem. Biomar. 16, 2226-2232, doi: 10.1158/1055-9965.epi-07-0599 (2007).
40. Agalliu, I., Salinas, C. A., Hansten, P. D., Ostrander, E. A. & Stanford, J. L. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J. Epidemiol. 168, 250-260, doi: 10.1093/aje/kwn141 (2008).
41. Coogan, P. F., Kelly, J. P., Strom, B. L. & Rosenberg, L. Statin and NSAID use and prostate cancer risk. Pharmacoepidem. Dr. S. 19, 752-755, doi: 10.1002/pds.1970 (2010).
42. Chang, C. C., Ho, S. C., Chiu, H. F. & Yang, C. Y. Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 71, 1818-1824, doi: 10.1002/pros.21401 (2011).
43. Vinogradova, Y., Coupland, C. & Hippisley-Cox, J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 11, 409, doi: 10.1186/1471-2407-11-409 (2011).
44. Jespersen, C. G., Norgaard, M., Friis, S., Skriver, C. & Borre, M. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. Cancer Epidemiol. 38, 42-47, doi: 10.1016/j.canep.2013.10.010 (2013).
45. Leung, H. W., Chan, A. L., Lo, D., Leung, J. H. & Chen, H. L. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin. Drug Saf. 12, 19-27, doi: 10.1517/14740338.2013.744392 (2013).
46. Olivan, M. et al. Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. Biomed Res. Int. 2015, 762178, doi: 10.1155/2015/762178 (2015).
47. Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279, 1615-1622 (1998).
48. Serruys, P. W. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 287, 3215-3222 (2002).
49. Disease)., L. S. G. L.-t. I. w. P. i. I. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 359, 1379-1387, doi: 10.1016/s0140-6736(02)08351-4 (2002).
50. Strandberg, T. E. et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 364, 771-777, doi: 10.1016/s0140-6736(04)16936-5 (2004).
51. Group., H. P. S. C. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. 3, 6, doi: 10.1186/1741-7015-3-6 (2005).
52. Ford, I. et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357, 1477-1486, doi: 10.1056/NEJMoa065994 (2007).
53. Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J. & White, C. M. Statins and cancer risk: a meta-Analysis. JAMA. 295, 74-80, doi: 10.1001/jama.295.1.74 (2006).
54. Kuoppala, J., Lamminpaa, A. & Pukkala, E. Statins and cancer: A systematic review and meta-Analysis. Eur. J. Cancer 44, 2122-2132, doi: 10.1016/j.ejca.2008.06.025 (2008).
55. Browning, D. R. & Martin, R. M. Statins and risk of cancer: a systematic review and metaanalysis. Int. J. Cancer 120, 833-843, doi: 10.1002/ijc.22366 (2007).
56. Hamilton, R. J., Goldberg, K. C., Platz, E. A. & Freedland, S. J. The influence of statin medications on prostate-specific antigen levels. J. Natl. Cancer Inst. 100, 1511-1518, doi: 10.1093/jnci/djn362 (2008).
57. Mondul, A. M., Caffo, B. & Platz, E. A. Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. Cancer Epidemiol. 35, e6-11, doi: 10.1016/j.canep.2010.11.005 (2011).